Dr Reddy's Labs Crashes 9% To 52-Week Low As Semaglutide Setback Wipes Out Nearly 70% Of Quarterly Profit

Shares of Dr Reddy's Laboratories, one of India's largest pharmaceutical companies by revenue, crashed nearly 9 per cent to hit a fresh 52-week low on Thursday, July 23, as investors reacted with alarm to a June-quarter earnings report that fell dramatically short of Street expectations. The stock tumbled as much as 8.70 per cent intraday to ₹1,080.05 on the BSE and declined 6.91 per cent on the NSE to touch ₹1,101, marking the stock's lowest level in more than a year, as the market digested a quarterly result that saw net profit collapse by 69.2 per cent year-on-year — one of the more severe single-quarter earnings disappointments of this year's results season across India's otherwise resilient pharmaceutical sector.

The headline numbers, disclosed after market hours on Wednesday, July 22, told a stark story. Dr Reddy's reported consolidated net profit attributable to owners of the company of ₹4,435 crore for the April-June quarter of FY27, a steep decline from ₹14,178 crore in the corresponding quarter of the previous fiscal year. Revenue for the quarter also declined, falling roughly 5.5 per cent year-on-year, a combination of a shrinking top line and a collapsing bottom line that immediately triggered alarm among analysts who had, going into the results, been modelling a considerably more modest earnings profile for the quarter, even accounting for known headwinds in the company's core generics business.

At the heart of the earnings collapse was a significant one-time provision tied to the company's semaglutide business — the increasingly important weight-loss and diabetes drug category that has become one of the most closely watched growth opportunities across the global pharmaceutical and generics industry following the commercial success of branded GLP-1 medications. Dr Reddy's had been positioning itself as an early mover in the semaglutide generics and biosimilar space, but the company took a substantial inventory write-off provision during the quarter linked to a disruption in semaglutide API supplies, a setback that management indicated would keep the product effectively out of commercial circulation until a resumption expected around November, according to details shared during the company's post-results earnings call.

During that earnings call, company leadership fielded detailed questions from sell-side analysts probing the scale of the semaglutide disruption's financial impact. In response to one such query about the opportunity lost as a result of the API supply provision, management indicated the disruption represented a lost sales opportunity in the range of approximately three to four million pens, assuming the product returns to commercial availability by November as currently anticipated — a figure that underscores just how significant a single supply-chain disruption in a single emerging product category can be for a company of Dr Reddy's scale, particularly given the strategic importance the semaglutide opportunity has held in the company's forward growth narrative over the past several quarters.

Beyond the semaglutide-specific provision, the quarter also reflected broader softness across Dr Reddy's core generics business, with the revenue miss concentrated particularly in the company's North America, Europe, and Russia markets, only partially offset by relatively stronger performance from its India and rest-of-world businesses. Elara Securities, in a research note following the results, characterised the quarter as significantly below expectations, with revenue and EBITDA missing estimates by roughly 9 per cent and 31 per cent respectively — a scale of miss on the profitability line considerably larger than the revenue shortfall alone, pointing to meaningful margin compression running through the business beyond just the isolated semaglutide provision. The brokerage noted EBITDA margin, even after adjusting for the one-off semaglutide inventory write-off, came in at around 13.3 per cent, significantly below both the brokerage's own estimate and the broader Street's expectation, which had been pointing toward margins in the high teens.

The market's reaction to the results has been swift and severe, with the stock's initial post-results decline of nearly 9 per cent on Thursday building on a smaller decline already seen in Wednesday's session ahead of the results announcement — meaning the stock has now shed a meaningful chunk of its value over just two trading sessions. Multiple global brokerages moved quickly to cut their price targets on the stock following the results, with names including CLSA, Nomura, Goldman Sachs, and Citi among those revising their estimates downward, reflecting a broad-based reassessment of the company's near-term earnings trajectory across the sell-side analyst community covering the stock.

The stock's American Depositary Receipts also registered a sharp decline, falling roughly 9 per cent in a comparable move that reflected the same disappointing fundamentals being digested by both domestic and international investors holding exposure to the company through its ADR listing. That kind of synchronised sell-off across both the domestic listing and the ADR is typically read by market participants as confirmation that the negative reaction reflects a genuine reassessment of company fundamentals rather than any technical or India-specific market-structure factor in isolation.

For context on the scale of the decline, Dr Reddy's shares had touched a 52-week high of ₹1,414.90 as recently as June 29, 2026 — meaning the stock has fallen by well over 20 per cent from that peak in under a month, a dramatic reversal for a stock that had, earlier in the year, been viewed by several analysts as one of the more attractively positioned names within India's pharmaceutical sector given its semaglutide optionality and broader generics pipeline. On a year-to-date basis, the stock has now moved into negative territory, having lost around 6 per cent since the start of calendar 2026, while its one-month decline of roughly 8.5 per cent underscores just how concentrated the damage has been in the period immediately surrounding this quarter's results.

Brokerages covering the stock have, in their post-results commentary, converged on a common theme: that the pace and shape of Dr Reddy's earnings recovery over the coming quarters will hinge substantially on two specific catalysts — the timely resumption of semaglutide API supplies, expected around November per management's own guidance, and regulatory approval for the company's biosimilar abatacept product, a rheumatoid arthritis treatment that has been positioned as another meaningful growth driver in the company's broader biosimilars pipeline. Until clarity emerges on both fronts, analysts have generally adopted a more cautious near-term stance on the stock, even while several have stopped short of turning outright bearish given the company's longer-term positioning in the global generics and biosimilars space.

The episode also carries broader read-through implications for how investors are pricing execution risk across India's pharmaceutical sector's growing bets on complex, high-value generic and biosimilar categories like GLP-1 drugs. As more Indian pharmaceutical majors chase opportunities in this increasingly crowded and commercially lucrative category, Dr Reddy's supply-chain stumble this quarter serves as a pointed reminder of just how operationally complex and disruption-prone these newer, more technically demanding manufacturing categories can prove relative to the company's traditional, more mature generics business lines — a risk factor that sell-side analysts covering peer companies pursuing similar GLP-1 opportunities are likely to be scrutinising more closely in the wake of this quarter's results.

For now, Dr Reddy's finds itself in the uncomfortable position of having to rebuild market confidence from a considerably weakened starting point, with the stock's near-term trajectory likely to remain hostage to incremental updates on the semaglutide supply-chain resolution timeline and any further clarity on the broader biosimilar approval pipeline that management has repeatedly pointed to as the company's key medium-term growth catalysts. Whether the stock can stabilise around current levels or faces further downside in the sessions ahead will depend, in large part, on whether management's November resumption guidance for semaglutide supplies holds — a date that has, almost overnight, become one of the most closely watched near-term catalysts across India's pharmaceutical sector.

The broader competitive dynamics within the global semaglutide and GLP-1 generics landscape add further complexity to Dr Reddy's recovery narrative. As the patent landscape around branded GLP-1 medications continues to evolve across different global markets, generic and biosimilar manufacturers including Dr Reddy's have been racing to position themselves for what analysts widely expect to be one of the largest addressable opportunities in the generics industry's recent history, given the scale of global demand for weight-management and diabetes medications in this therapeutic class. A supply-chain disruption of the kind Dr Reddy's experienced this quarter, while framed by management as a temporary, resolvable issue, nonetheless raises legitimate questions among analysts about execution risk at exactly the moment when competitive positioning in this emerging category matters most, given how quickly rival generic manufacturers — both Indian and international — are racing to establish their own manufacturing and supply capabilities in the same category.

Dr Reddy's broader financial position, despite this quarter's earnings disappointment, remains one that most covering analysts continue to view as fundamentally sound, with the company's balance sheet strength and diversified revenue base across multiple geographies and therapeutic categories providing a degree of resilience that more narrowly focused or more heavily leveraged peers might lack when navigating a comparable single-quarter setback. That balance sheet resilience is likely to factor into how patient covering analysts remain with the stock, even as near-term price targets have been trimmed across the board following this week's results.

Investor attention in the coming weeks is also likely to turn toward how Dr Reddy's peers within India's pharmaceutical sector navigate their own exposure to similar supply-chain and execution risks within complex, high-value generic categories, given that several other major Indian pharmaceutical companies have also been pursuing their own GLP-1 and biosimilar strategies as part of broader efforts to diversify beyond more commoditised, lower-margin traditional generics businesses. Should peer companies report similar supply-chain-related disruptions in categories they've been counting on for future growth, it could reinforce a broader sector-wide re-rating of execution risk premiums being applied to India's pharmaceutical majors as they collectively chase increasingly complex, higher-value manufacturing opportunities.

Analysts will also be watching closely for any updated guidance from Dr Reddy's management on the broader FY27 outlook when the company next communicates with investors, given how significantly this quarter's results have shifted the base case assumptions embedded in most sell-side financial models for the company. Until that clarity emerges, the stock is likely to remain one of the more actively debated names within India's pharmaceutical sector — a genuine test case for how quickly, and how completely, a well-established pharmaceutical major can recover from a single-quarter operational setback of this magnitude. For now, shareholders are left balancing a genuinely disappointing quarter against a still-credible longer-term growth story, a combination that typically keeps a stock volatile until the next meaningful data point arrives. theimpactfulglobalindian.com will continue tracking brokerage revisions and any fresh management commentary on the semaglutide supply timeline as it emerges, given how directly that single supply-chain update is now likely to move the stock in either direction once it lands. In the meantime, the stock's valuation will likely continue to reflect a market pricing in genuine uncertainty rather than confident conviction in either direction, a fair reflection, arguably, of just how much now genuinely hinges on a single supply chain resuming on schedule. It is a reminder, too, of how quickly a single operational setback in a single emerging product category can reshape the market's entire narrative around an otherwise large, diversified, multi-decade pharmaceutical franchise — underscoring just how much weight investors have come to place on the newest, highest-growth parts of a company's pipeline, sometimes at the expense of appreciating the stability of its more established, legacy businesses. That imbalance in how the market weighs new-versus-old revenue streams is likely to remain a recurring theme across India's pharmaceutical sector as more companies chase similarly high-stakes, high-reward categories in the years ahead, making this week's events at Dr Reddy's a case study that rival managements and their own investors will likely study closely in the months to come, well beyond the immediate confines of this single earnings season.